According to a recent article in Forbes this may well be the case. The argument is that as a result of highly differentiated healthcare delivery not perhaps providing the value added clinical and economic benefits – patients may have to turn to a more generic (and effective?) form of healthcare delivery.
While this story is mainly about pharmaceuticals it may well apply to homecare products as is evidenced by NCART – National Coalition For Assistive And Rehab Technology and others actively campaigning to have complex rehab products excluded from the National Competitive Bidding program.
